1
HAMED EHAB: Abuse-resistant formulations. CIMA LABS, Oehler Ross J, September 1, 2011: WO/2011/106416 (22 worldwide citation)

This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than abo ...


2
Jayyosi Zaid, Mcgeehan Gerard M, Kelley Michael F, Labaudiniere Richard F, Zhang Litao, Caulfield Thomas J, Minnich Anne, Bobko Mark, Morris Robert, Groneberg Robert D, Mcgarry Daniel G: Tri-aryl acid derivatives as ppar receptor ligands. Aventis Pharma Deutschland, Jayyosi Zaid, Mcgeehan Gerard M, Kelley Michael F, Labaudiniere Richard F, Zhang Litao, Caulfield Thomas J, Minnich Anne, Bobko Mark, Morris Robert, Groneberg Robert D, Mcgarry Daniel G, OEHLER Ross J, November 2, 2000: WO/2000/064876 (5 worldwide citation)

This invention is directed to triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor. In formula (I), (a), (b), and (c) are independen ...


3
HAMED EHAB: Abuse-resistant formulations. CIMA LABS, Oehler Ross J, July 14, 2011: WO/2011/084593 (1 worldwide citation)

This disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 p ...


4
Spada Alfred P, He Wei, Myers Michael R: Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors. Aventis Pharmaceuticals Products, Spada Alfred P, He Wei, Myers Michael R, OEHLER Ross J, June 2, 2000: WO/2000/031049

This invention is directed to quinoline/quinoxaline compounds of formula (I) wherein X is L¿1?OH or L¿2?Z¿2?; L¿1? is (CR¿3a?R¿3b?)¿r? or (CR¿3a?R¿3b?)¿m?-Z¿3?-(CR¿3'a?R¿3'b?)¿n?; L¿2? is (CR¿3a?R¿3b?)¿p?-Z¿4?-(CR¿3'a?R¿3'b?)¿q? or ethenyl; Z¿1? is CH or N; Z¿2? is optionally substituted hydroxycycl ...


5
Myers Michael R, Spada Alfred P, Persons Paul E, Maguire Martin P: Quinoline and quinoxaline compounds. Aventis Pharmaceuticals Products, Myers Michael R, Spada Alfred P, Persons Paul E, Maguire Martin P, OEHLER Ross J, June 2, 2000: WO/2000/031050

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use fo these compounds for treating a patient suffering from or subject to diso ...


6
Myers Michael R, He Wei, Spada Alfred P, Maguire Martin P: Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors. Aventis Pharmaceuticals Products, Myers Michael R, He Wei, Spada Alfred P, Maguire Martin P, OEHLER Ross J, June 2, 2000: WO/2000/031051

This invention is directed to quinoline/quinoxaline compounds of formula (I), which inhibit platelet-derived growth factor or p56?lck¿ tyrosine kinase activity, to pharmaceutical compositions comprising theses compounds, and to the use of these compounds for treating a patient suffering from or subj ...


7

8
Herpin Timothy F, Morton George, Salvino Joseph M: Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives. Aventis Pharmaceuticals Products, Herpin Timothy F, Morton George, Salvino Joseph M, OEHLER Ross J, December 21, 2000: WO/2000/077519

A method for the solid phase synthesis of N,N-disubstituted diazacycloalkylcarboxy derivatives of general formula (I) and (II) is claimed. Examples include piperazine-2-carboxamide. The method is applicable to the synthesis or large combinatorial libraries.


9
Won Chong Min, Strohbeck Christianna L, Tang Sheng Yuh, Hsu Bih Hsiung: Stabilized steroid compositions. Rhone Poulenc Rorer Pharmaceuticals, Won Chong Min, Strohbeck Christianna L, Tang Sheng Yuh, Hsu Bih Hsiung, OEHLER Ross J, December 19, 1996: WO/1996/040042

The degradation of triamcinolone acetonide in aqueous solutions is studied under accelerated storage conditions of 70 °C over the pH range 1-10. Trace level metal ions can markedly accelerate the oxidative degradation in neutral and basic solutions, but pH conditions and/or the inclusion of metal-se ...


10
Dankulich William P, Mcgarry Daniel G, Burns Christopher, Gallagher Timothy F, Volz Francis A: Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors. Aventis Pharmaceuticals Products, Dankulich William P, Mcgarry Daniel G, Burns Christopher, Gallagher Timothy F, Volz Francis A, OEHLER Ross J, July 6, 2000: WO/2000/039087

This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula (I): wherein X is O, S or NR?1¿ which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to ...